ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

In This Article:

Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with Biosion for global rights (excluding Greater China) to two of the latter’s pipeline candidates, BSI-045B and BSI-502.

Biosion’s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis. Results from a completed phase IIa proof-of-concept study by Biosion demonstrated that BSI-045B has a pharmacodynamic, safety and efficacy profile indicative of its potential as a best-in-class therapy.

Several mid-stage studies of the candidate are ongoing in China for severe asthma and chronic rhinosinusitis with nasal polyps, aiming to accelerate potential proof-of-concept demonstrations for additional indications. The other investigational candidate, per the terms of the licensing deal, is BSI-502, a potential best-in-class, novel bispecific antibody that is directed against both TSLP and IL4R, which is currently in the preclinical stage. However, both candidates are yet to be evaluated by regulatory authorities.

Year to date, shares of Aclaris have skyrocketed 199% against the industry’s 6% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Per management, the licensing deal with Biosion concludes Aclaris’ strategic review process to maximize shareholders’ value. The addition of these two potentially transformative treatments is expected to complement Aclaris’ existing ITK inhibitor portfolio, resulting in a pipeline of differentiated assets that target multiple high-value immunologic and respiratory indications.

Aclaris’ pipeline currently comprises several candidates undergoing clinical development across various stages for skin disease and cancer indications.

Cash Consideration for the Deal Between ACRS and Biosion

Per the terms of the licensing agreement, Aclaris is liable to make a $30 million upfront payment to Biosion for the transfer of global rights to BSI-045B and BSI-502. Biosion is also entitled to receive $4.5 million for certain development costs and $6.2 million for certain development and drug product reimbursement from Aclaris.

Moreover, Aclaris is liable to make additional payments of up to $125 million upon the achievement of specified regulatory milestones and up to $795 million upon the achievement of specified sales milestones. Biosion also remains eligible to receive a tiered low-to-mid single-digit royalty based upon a percentage of annual net sales from Aclaris.

Waiting for permission
Allow microphone access to enable voice search

Try again.